The University of Leeds uses personally-identifiable information to conduct research to improve health, care and services. The University of Leeds has also sent your Initials, NHS number, Data of Birth and Postcode to NHS Digital and in return they will inform us if you have died, have been diagnosed with cancer, or have been admitted to hospital due to a complication. The only people at the University of Leeds who will have access to information that identifies you will be people who received, reviewed and entered your data on to the study database, the people who analysed your data or people who audit the data collection process. Your hospital will have passed these details to the University of Leeds along with the information collected from you and your medical records. ![]() ![]() Your hospital will have used your name, NHS number and postcode to make sure that relevant information about the study is recorded for your care, and to oversee the quality of the study. The NHS hospital which recruited you in to the research study (your hospital) will have collected information from you and your medical records needed for the research study from your medical records. What information do we collect about you? Both University of Leeds and UCL have used information from you and your medical records in order to undertake this study and act as the data controllers for this study. The University of Leeds has shared the data (anonymously) with the University College London (UCL) as this is where the doctors who are in charge of the study are based. The University of Leeds is sponsor for this study based in the United Kingdom. This information has been put together by the team of researchers responsible for the ELUCIDATE trial. This information is for the attention of participants of the ELUCIDATE trial and describes how the data you provided during your participation in the trial is being used and protected. For further information, please contact the cited source.ELF to Uncover Cirrhosis as an Indication for Diagnosis and Action for Treatable Events Note: material may have been edited for length and content. This article has been republished from the following materials. ![]() Elucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chips. ![]() Reference: Deguchi S, Kosugi K, Hashimoto R, et al. Organs-on-a-chip technology, such as the ones described in this study, will help to broaden the understanding of organ dysfunctions in COVID-19 patients and accelerate the development of therapeutic agents to treat this catastrophic disease. These findings suggest that the vascularized parts of the liver are more vulnerable to damage by SARS-CoV-2 infection, and such damage is responsible for the liver dysfunctions experienced by COVID-19 patients.įurthermore, the team screened for therapeutic drugs that can treat these liver abnormalities and found the combined treatment of remdesivir and baricitinib to significantly reduce the hepatotoxicity and lipid droplet accumulation observed in the infected bv-LoCs, suggesting that these two drugs could be effective to treat liver injuries caused by SARS-CoV-2 infection. Interestingly, despite observing viral clearance after two weeks, increased hepatotoxicity and lipid droplet accumulation continued in the infected bv-LoCs, but not in the infected ibd-LoCs. The researchers infected these LoCs with SARS-CoV-2 to model the liver pathophysiology of COVID-19 patients and detected the virus in both ibd-LoCs and bv-LoCs two days following infection. Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |